HUMAN MONOCLONAL ANTIBODY TO RESPIRATORY SYNCYTIAL VIRUS

呼吸道合胞病毒人单克隆抗体

• 批准号: 3489743
• 负责人: PETER BRAMS
• 金额: $ 4.49万
• 依托单位: IDEC PHARMACEUTICALS CORPORATION
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-09-30 至 1994-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489743
• 关键词: B lymphocyte; SCID mouse; antiviral antibody; cell fusion; cell line; cell transformation; human subject; hybrid cells; immunoglobulin genes; monoclonal antibody; neutralizing antibody; respiratory infections; respiratory syncytial virus; technology /technique development; transfection; transfection /expression vector; virus antigen; virus protein

DESCRIPTION: (Adapted from the applicant's abstract) Passive immunotherapy has been shown to be an effective method for controlling RSV infection. The virus envelope fusion (F protein) represents an ideal target for passive immunotherapy since antibodies to this protein typically bind to and neutralize both of the two clinical subgroups of this virus, A and B. In addition, antibodies to the F protein have been shown to provide protection in animal models of RSV. The goal of IDEC Pharmaceuticals' anti-RSV program is to produce human MAbs, which are capable of in vitro and in vivo neutralization and which are useful for the treatment of this significant pathogen. Human B cells will be immortalized using three approaches: EBV transformation, somatic cell fusion, and hu-SCID mouse expansion followed by EBV transformation. Immortalized human B cells will be screened for antibody activity to the F protein. F protein reactive B cells will be cloned and their antibodies tested for virus-neutralizing activity. The immunoglobulin genes from the selected B cell clones will be transfected into a mammalian expression system for generation of antibodies for clinical evaluation.

描述：（改编自申请人的摘要）被动 免疫疗法已被证明是一种有效的方法， RSV感染。 病毒包膜融合体（F蛋白）代表了一种 被动免疫治疗理想靶点，因为针对该蛋白质的抗体 通常结合并中和两个临床亚组 这个病毒A和B 此外，针对F蛋白的抗体已经被 显示在RSV动物模型中提供保护。 IDEC的目标 制药公司的抗RSV计划是生产人单克隆抗体， 其能够在体外和体内中和，并可用于 治疗这种重要的病原体。 人类B细胞将 使用三种方法永生化：EBV转化，体细胞 融合，和hu-SCID小鼠扩增，随后进行EBV转化。 将筛选永生化人B细胞的抗体活性， F蛋白。 F蛋白反应性B细胞将被克隆，其 测试抗体的病毒中和活性。免疫球蛋白 将来自所选B细胞克隆的基因转染到 用于产生临床用抗体的哺乳动物表达系统 评价